SLC5A2 and type 2 diabetes mellitus: In the present study, the patients who received SGLT-2 inhibitors for T2DM and had concomitant CAD reported a numerically higher incidence of genital infections as compared to those without CAD but the difference was not statistically significant (p=0.712).